3 results
Primary:• To compare overall survival (OS) in patientsrandomized to NGR-hTNF plus BIC versuspatients randomized to placebo plus BICSecondary:• To compare progression-free survival (PFS)• To compare disease control rate (DCR, defined asthe percentage…
Currently, caplacizumab is being developed for treatment of acquired thrombotic thrombocytopenic purpura (TTP). TTP is a rare and potentially life-threatening thrombotic microangiopathy, in which accumulation of ULvWF multimers leads to an increased…
Objective: Primary : To compare the difference in glucose nadir during the MMT on and off pre-treatment with colesevelam in RYGB-CCx patients with a hypoglycaemia (RYGB-CCx-hypo) in the first MMT Secondary:To evaluate the difference in number of…